Login | Register

Denosumab (Xgeva) Not Approved For Metastasis Prevention

Amgen's application for expanded indications for denosumab (Xgeva) were turned down by the FDA (Food and Drug Administration) - the expanded indications were to include bone metastases prevention in patients with castration-resistant prostate cancer...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *